| 05/11 | Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director | CI |
| 02/27 | Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022 | CI |
| 01/30 | Hexima Limited Declares Voting Results | CI |
| 01/03 | Arovella Therapeutics Appoints COO | MT |
| 2022 | Hexima Acting CEO to Step Down | MT |
| 2022 | Nicole Van Der Weerden to Step Down as CEO of Hexima Limited | CI |
| 2022 | Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office | MT |
| 2022 | Hexima Limited Receives Requisition Notice from Merchant Biotech Fund | CI |
| 2022 | Hexima Limited Announces Board Changes | CI |
| 2022 | 10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC.. | CI |
| 2022 | 6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o.. | CI |
| 2022 | Hexima : 2022 Annual Financial Report | PU |
| 2022 | Hexima Limited Announces Change of Address | CI |
| 2022 | Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022 | CI |
| 2022 | Hexima Managing Director, CEO Steps Down | MT |
| 2022 | Hexima Limited Announces Management Changes | CI |
| 2022 | Hexima : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr | PU |
| 2022 | Hexima Limited Announces Phase II Results of Pezadeftide | CI |
| 2022 | Australian Shares Jump on IT Boost Amid Bargain Hunting | MT |
| 2022 | Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive.. | MT |
| 2022 | Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide | CI |
| 2022 | Hexima : ShareCafe Presentation | PU |
| 2022 | Hexima : Notification regarding unquoted securities - HXL | PU |
| 2022 | Hexima : Investor Webinar on Today | PU |
| 2022 | Hexima : Application for quotation of securities - HXL | PU |
| 2022 | Hexima : Appendix 4D and Interim Financial Statements | PU |
| 2022 | Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2021 | CI |
| 2022 | Hexima : Notification regarding unquoted securities - HXL | PU |
| 2022 | Hexima : Application for quotation of securities - HXL | PU |
| 2022 | Hexima : Quarterly Activities Report and Appendix 4C | PU |
| 2022 | Hexima Appoints Commercial Chief | MT |
| 2022 | Phillip Rose Appoints Phillip Rose as Chief Commercial Officer | CI |
| 2021 | Hexima : Notification regarding unquoted securities - HXL | PU |
| 2021 | Hexima : Notification regarding unquoted securities - HXL | PU |
| 2021 | Hexima Names New Chief Development Officer | MT |
| 2021 | Hexima : CEO's Presentation | PU |
| 2021 | Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director | CI |
| 2021 | Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso.. | CI |
| 2021 | Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer | CI |
| 2021 | Hexima Completes Oversubscribed Share Purchase Plan | MT |
| 2021 | Hexima : Application for quotation of securities - HXL | PU |
| 2021 | Hexima Limited Announces Company Secretary Change | CI |
| 2021 | 3,559,437 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o.. | CI |
| 2021 | Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 Septembe.. | CI |
| 2021 | Hexima : 2021 Annual Financial Report | PU |
| 2021 | Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021 | CI |
| 2021 | Hexima Limited Auditor Raises 'Going Concern' Doubt | CI |
| 2021 | Hexima : Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surge.. | MT |
| 2021 | Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging | CI |
| 2021 | Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial | CI |
| 2021 | Hexima : Expects to Secure European Patent for Nail Fungal Infection Treatment | MT |
| 2021 | Hexima Limited Extends Its Patent Protection for Pezadeftide | CI |
| 2021 | Hexima : Fungal Nail Infection Treatment Receives INN Designation | MT |
| 2021 | Hexima : Secures Patent for Fungal Nail Infection Treatment | MT |
| 2021 | Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 .. | CI |
| 2021 | Hexima : R&D Webinar on TodayOpens in a new Window | PU |
| 2021 | Hexima : SAB Formation and R&D Video ConferenceOpens in a new Window | PU |
| 2021 | Hexima : Half Year Report and AccountsOpens in a new Window | PU |
| 2021 | Hexima Limited Announces Earnings Results for the Six Months Ended 31 December 2020 | CI |
| 2021 | Hexima Limited Updates Timeline to Phase 2B Results | CI |
| 2020 | Hexima Limited has completed an IPO in the amount of AUD 3.280771 million. | CI |
| 2020 | Hexima Limited Reports Earnings Results for the Year Ended June 30, 2019 | CI |
| 2020 | Hexima Limited has filed an IPO in the amount of AUD 7.5 million. | CI |
| 2020 | Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2020 | CI |
| 2020 | Hexima Limited Auditor Raises 'Going Concern' Doubt | CI |
| 2020 | Hexima Limited announced that it has received AUD 5.5 million in funding | CI |
| 2019 | Hexima Limited Auditor Raises 'Going Concern' Doubt | CI |
| 2012 | Hexima Limited Announces Unaudited Consolidated Earnings Results for Six Months Ended D.. | CI |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
